Journal of Cardiothoracic Surgery, Journal Year: 2024, Volume and Issue: 19(1)
Published: Nov. 8, 2024
Observational studies and experimental evidence have shown that chemokines play important roles in lung cancer development, progression, treatment. However, few examined the causal association between them.
Language: Английский
Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15
Published: April 16, 2024
Tertiary lymphoid structure (TLS) is an ectopic lymphocyte aggregate formed in peripheral non-lymphoid tissues, including inflamed or cancerous tissue. Tumor-associated TLS serves as a prominent center of antigen presentation and adaptive immune activation within the periphery, which has exhibited positive prognostic value various cancers. In recent years, concept maturity regarding been proposed mature TLS, characterized by well-developed germinal centers, exhibits more potent tumor-suppressive capacity with stronger significance. Meanwhile, evidence showed that can be induced therapeutic interventions during cancer treatments. Thus, evaluation induce its formation are critical issues current research. this review, we aim to provide comprehensive summary existing classifications for strategies capable inducing tumors.
Language: Английский
Citations
18
Signal Transduction and Targeted Therapy, Journal Year: 2024, Volume and Issue: 9(1)
Published: Aug. 28, 2024
Tertiary lymphoid structures (TLSs) are defined as aggregates formed in non-hematopoietic organs under pathological conditions. Similar to secondary (SLOs), the formation of TLSs relies on interaction between tissue inducer (LTi) cells and organizer (LTo) cells, involving multiple cytokines. Heterogeneity is a distinguishing feature TLSs, which may lead differences their functions. Growing evidence suggests that associated with various diseases, such cancers, autoimmune transplant rejection, chronic inflammation, infection, even ageing. However, detailed mechanisms behind these clinical associations not yet fully understood. The by TLS maturation localization affect immune function also unclear. Therefore, it necessary enhance understanding development at cellular molecular level, allow us utilize them improve microenvironment. In this review, we delve into composition, mechanism, potential therapeutic applications TLSs. Furthermore, discuss implications role markers response prognosis. Finally, summarize methods for detecting targeting Overall, provide comprehensive aim develop more effective strategies.
Language: Английский
Citations
15
Journal of Clinical Investigation, Journal Year: 2025, Volume and Issue: 135(7)
Published: March 31, 2025
Tertiary lymphoid structures (TLS) in the tumor microenvironment (TME) are emerging solid-tumor indicators of prognosis and response to immunotherapy. Considering that tumorigenesis requires metabolic reprogramming subsequent TME remodeling, discovery TLS regulators is expected produce immunotherapeutic targets. To identify such regulators, we constructed a metabolism-focused sgRNA library performed an vivo CRISPR screening orthotopic lung mouse model. Combined with The Cancer Genome Atlas database analysis TLS-related hub genes, found loss Acat1 cells sensitized tumors anti-PD1 treatment, accompanied by increased TME. Mechanistic studies revealed ACAT1 resulted mitochondrial protein hypersuccinylation subsequently enhanced oxidative metabolism, which impeded formation. Elimination ROS NAC or knockdown promoted B cell aggregation construction. Consistently, data from tissue microassays 305 patients cancer showed were more abundant non-small (NSCLC) tissues lower expression. Intratumoral expression was associated poor immunotherapy outcomes NSCLC. In conclusion, our results identified as regulator promising target
Language: Английский
Citations
1
MedComm, Journal Year: 2024, Volume and Issue: 5(3)
Published: March 1, 2024
Abstract Cancer is a major cause of death globally, and traditional treatments often have limited efficacy adverse effects. Immunotherapy has shown promise in various malignancies but less effective tumors with low immunogenicity or immunosuppressive microenvironment, especially sarcomas. Tertiary lymphoid structures (TLSs) been associated favorable response to immunotherapy improved survival cancer patients. However, the immunological mechanisms clinical significance TLS malignant are not fully understood. In this review, we elucidate composition, neogenesis, immune characteristics tumors, as well inflammatory development. An in‐depth discussion unique TLSs lung cancer, breast melanoma, soft tissue sarcomas will be presented. Additionally, therapeutic implications TLS, including its role marker prognosis, strategies promote formation maturation explored. Overall, aim provide comprehensive understanding tumor microenvironment suggest potential interventions for treatment.
Language: Английский
Citations
5
Cancer Letters, Journal Year: 2024, Volume and Issue: 592, P. 216922 - 216922
Published: May 3, 2024
Language: Английский
Citations
5
Molecular Biology Reports, Journal Year: 2025, Volume and Issue: 52(1)
Published: Feb. 4, 2025
Language: Английский
Citations
0
Cancer Science, Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 25, 2025
ABSTRACT Undifferentiated pleomorphic sarcoma (UPS) has a favorable objective response rate to anti‐PD‐1 drugs compared with other sarcomas. Tertiary lymphoid structure (TLS) is prognostic factor and biomarker for immune checkpoint inhibitors (ICIs). Nevertheless, there are limited data on the tumor microenvironment (TME) support good ICIs in sarcoma. Therefore, this study was conducted investigate impact of TLS prognosis TME. A total 52 UPS wide resection were divided into intratumoral TLS, extratumoral without groups. Survival analysis immunohistochemistry performed evaluate cells molecules, multiplexed immunofluorescence T‐cell exhaustion among three detected 34 cases (65%), including 23 (44%) 11 (21%) cases. Patients had significantly longer overall survival than those (log rank p = 0.020). The group higher number expression PD‐L1 IDO‐1 group. Progenitor‐exhausted T also observed patients UPS. In conclusion, these findings could help predict demonstrated be Intratumoral may ICIs, especially drugs.
Language: Английский
Citations
0
Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 14
Published: Dec. 4, 2023
The success of immunotherapy approaches, such as immune checkpoint blockade and cellular with genetically modified lymphocytes, has firmly embedded the system in roadmap for combating cancer. Unfortunately, majority cancer patients do not yet benefit from these therapeutic even when prognostic relevance response their tumor entity been demonstrated. Therefore, there is a justified need to explore new strategies inducing anti-tumor immunity. recent connection between formation ectopic lymphoid aggregates at sites patient prognosis, along an effective response, suggests that manipulating occurrence tertiary structures (TLS) may play critical role activating against growing tumor. However, mechanisms governing TLS clear understanding substantial heterogeneity are still lacking. Here, we briefly summarize current state knowledge regarding driving development, outline impact on clinical outcomes patients, discuss appropriate systems modeling help identify protective patients.
Language: Английский
Citations
8
The FASEB Journal, Journal Year: 2024, Volume and Issue: 38(14)
Published: July 17, 2024
G protein-coupled receptors (GPCRs) are essential contributors to tumor growth and metastasis due their roles in immune cell regulation. Therefore, GPCRs potential targets for cancer immunotherapy. Here, we discuss the current understanding of signaling pathways progression from an immunocellular perspective. Additionally, focus on regulating checkpoint proteins involved evasion. Finally, review progress clinical trials GPCR-targeted drugs treatment, which may be combined with immunotherapy improve treatment efficacy. This expanded role shed light mechanisms underlying provide a novel perspective
Language: Английский
Citations
2
International Journal of Surgery, Journal Year: 2024, Volume and Issue: 110(4), P. 2275 - 2287
Published: Jan. 23, 2024
Background: Neoadjuvant chemoimmunotherapy (NACI) is promising for resectable nonsmall cell lung cancer (NSCLC), but predictive biomarkers are still lacking. The authors aimed to develop a model based on pretreatment parameters predict major pathological response (MPR) such an approach. Methods: enrolled operable NSCLC treated with NACI between March 2020 and May 2023 then collected baseline clinical-pathology data routine laboratory examinations before treatment. efficacy safety of this cohort was reported variables were screened by Logistic Lasso regression nomogram developed. In addition, receiver operating characteristic curves, calibration decision curve analysis used assess its power. Finally, internal cross-validation external validation performed the power model. Results: total, 206 eligible patients recruited in study 53.4% (110/206) achieved MPR. Using multivariate analysis, constructed seven variables, prothrombin time (PT), neutrophil percentage (NEUT%), large platelet ratio (P-LCR), eosinophil (EOS%), smoking, type, programmed death ligand-1 (PD-L1) expression finally. had good discrimination, area under (AUC) 0.775, 0.746, 0.835 all datasets, cross-validation, validation, respectively. curves showed consistency, indicated potential value clinical practice. Conclusion: This real world revealed favorable NACI. proposed multiple clinically accessible could effectively MPR probability be powerful tool personalized medication.
Language: Английский
Citations
0